| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 07/31/2003 | US20030144477 Therapy for autoimmune disease; major histocompatibility complex; side effect reduction; myasthenia gravis |
| 07/31/2003 | US20030144474 T cell receptor and a biologically active polypeptide with different recognition biding sites connected by a peptide linker; designed to redirect the immune system against various diseases |
| 07/31/2003 | US20030144358 Inhibition of platelet receptors for thrombin/fibrinogen to inhibit transplant rejection |
| 07/31/2003 | US20030144340 By inhibiting fetal cardiac gene expression and interfering with sarcomeric organization |
| 07/31/2003 | US20030144328 Compounds which inhibit leukocyte adhesion mediated by VLA-4 |
| 07/31/2003 | US20030144298 Therapeutic combinations of antihypertensive and antiangiogenics agents |
| 07/31/2003 | US20030144295 A synergistic antiischemic mixture of a tissue plasminogen activator, e.g. alteplase, pamiteplase, and zonampanel(7-imidazol-1-yl-6-nitro-2,3-dioxo-1,2,3,4-tetrahydroquinoxalin -1-yl acetic acid for strokes or cerebral infarctions |
| 07/31/2003 | US20030144265 HIV protease inhibitors based on amino acid derivatives |
| 07/31/2003 | US20030144264 Carbapenems containing a carboxy substituted phenyl group and useful for treating bacterial infections in mammals and humans |
| 07/31/2003 | US20030144261 A cyclic peptide useful for treating eating disorder and diabetes |
| 07/31/2003 | US20030144252 Bicalutamide and N-(3-chloro-4-fluorophenyl)-7-methoxy-6-(3-morpholinopropoxy)quinazolin-4 -amine used as inhibitor of prostate cancer |
| 07/31/2003 | US20030144248 Surfactant prevention of lung complications from cancer chemotherapy |
| 07/31/2003 | US20030144242 Antisense modulation of MEKK4 expression |
| 07/31/2003 | US20030144241 Antisense modulation of Smad6 expression |
| 07/31/2003 | US20030144240 Antisense strategy to modulate estrogen receptor response (ER alpha and/or ER beta) |
| 07/31/2003 | US20030144239 Expression system |
| 07/31/2003 | US20030144233 Conformation-activity relationship of apoptosis-inducing phosphodiester oligonucleotides |
| 07/31/2003 | US20030144232 Expression system |
| 07/31/2003 | US20030144227 Pharmaceutical composition comprising Nit2 for use in inhibiting tumor cell growth |
| 07/31/2003 | US20030144225 A nucleic acid hybrids for inhibiting gene expression, antiinflammation to treat infections, suppress HIV infection |
| 07/31/2003 | US20030144224 Antisense modulation of B-cell associated protein expression |
| 07/31/2003 | US20030144223 Antisense modulation of connective tissue growth factor expression |
| 07/31/2003 | US20030144222 Cyclodextrin grafted biocompatible amphilphilic polymer and methods of preparation and use thereof |
| 07/31/2003 | US20030144221 Antisense modulation of BCL2-associated X protein expression |
| 07/31/2003 | US20030144213 Combination therapy of angiotensin converting enzyme inhibitor, side-effect reduced amount of aldosterone antagonist and diuretic for treatment of cardiovascular disease |
| 07/31/2003 | US20030144211 Inhibit leukocyte adhesion to endothelium or to platelets |
| 07/31/2003 | US20030144210 Treatment of neurologic and psychiatric disorders |
| 07/31/2003 | US20030144209 Bone anabolic agents for the treatment of bone disease |
| 07/31/2003 | US20030144208 Polynucleotides and polypeptides that are members of the family of proteins bearing a collagen-like domain and a globular domain; promoting blood flow |
| 07/31/2003 | US20030144207 Hydrophilic conjugate having a peptide that is capable of passing the blood-brain barrier covalently linked to a water-soluble nonpeptidic polymer |
| 07/31/2003 | US20030144206 Combined use of a GLP-1 compound and modulator of diabetic late complications |
| 07/31/2003 | US20030144205 Polynucleotide sequence encoding a polypeptide comprising an amino acid sequence that modulates protein degradation during gametogenesis and early development |
| 07/31/2003 | US20030144203 Methods for slowing senescence and treating and preventing diseases associated with senescence |
| 07/31/2003 | US20030144202 Uses of keratinocyte growth factor-2 |
| 07/31/2003 | US20030144201 Use of HMGB fragments as anti-inflammatory agents |
| 07/31/2003 | US20030144200 Novel forms of the angiogenic factor vascular endothelial cell growth factor: VEGF |
| 07/31/2003 | US20030144199 Modified ciliary neurotrophic factor, method of making and methods of use thereof |
| 07/31/2003 | US20030144197 Autologous growth factor cocktail composition, method of production and use |
| 07/31/2003 | US20030144196 Derived from a cDNA subtraction library constructed from human peripheral blood T lymphocytes activated with antibodies against CD3 and CD28 cell surface antigens |
| 07/31/2003 | US20030144195 Therapeutic peptide-based constructs |
| 07/31/2003 | US20030144194 Cancer treatment and prognosis |
| 07/31/2003 | US20030144193 For the prevention or amelioration of symptoms of anthrax; fusion polypeptides |
| 07/31/2003 | US20030144190 Apoptosis modulation in fast growing cells and induction and/or stimulation of proapoptotic pathway in fast growing cells, especially in Ras-induced malignancies |
| 07/31/2003 | US20030144187 Comprising an osteoprotegerin polypeptide and an immunoglobulin FC region; treatment of bone disorders |
| 07/31/2003 | US20030144186 Conformationally constrained backbone cyclized peptide analogs |
| 07/31/2003 | US20030144184 Nonhemolytic, exhibit minimal in vitro cytotoxicity; treatment of bacterial and/or viral infection, especially one caused by HIV-1 retrovirus or other sexually-transmitted pathogens |
| 07/31/2003 | US20030144183 Synthetic glycosulfopeptides and methods of synthesis thereof |
| 07/31/2003 | US20030144182 CD40-Ligand lacking native-pattern glycosylation |
| 07/31/2003 | US20030144181 Insoluble compositions for controlling blood glucose |
| 07/31/2003 | US20030144180 Contains as active ingredient a therapeutically effective amount of agent for either enhancing protein kinase c production and/or activation |
| 07/31/2003 | US20030144179 Compositions containing peptide and electrolyte excretion promoter and foods containing the same |
| 07/31/2003 | US20030144176 Methods and compositions relating to MEK5 and cardiac hypertrophy and dilated cardiomyopathy |
| 07/31/2003 | US20030144175 Protease inhibitors |
| 07/31/2003 | US20030143759 Measuring in an assay containing the sample and a substrate for activated protein c, the conversion of the substrate by activated protein c and correlating to the functional activity |
| 07/31/2003 | US20030143739 Composition of restricted cancer cells which produce cancer cell proliferation suppressive materials, and uses thereof |
| 07/31/2003 | US20030143738 Compositions and methods for treating ischemic stroke |
| 07/31/2003 | US20030143735 Contacting human vpr interacting protein with a test compound and comparing the affinity of the vpr in the presence and absence of it |
| 07/31/2003 | US20030143734 Amino acid transporters and uses |
| 07/31/2003 | US20030143733 Tetrapeptide |
| 07/31/2003 | US20030143732 RNA interference mediated inhibition of adenosine A1 receptor (ADORA1) gene expression using short interfering RNA |
| 07/31/2003 | US20030143729 Also animal models; use determining substrate binding, detecting expression, drug screening, and treatments for diseases or conditions related to 4-aminobutyric acid (GABA) or taurine transporters |
| 07/31/2003 | US20030143713 Novel glycosidase inhibitors and their pharmacological uses, in particular for treating diabetes |
| 07/31/2003 | US20030143712 Nucleic acid; use identifying the enzyme inhibitors which are used as antitumor agents; detection of cells expressing the enzyme |
| 07/31/2003 | US20030143708 Method and reagent for the treatment of alzheimer's disease |
| 07/31/2003 | US20030143706 Novel human leucine-rich repeat containing protein expressed predominately in bone marrow, HLRRBM1 |
| 07/31/2003 | US20030143697 Nucleic acid encoding a fusion polypeptide that forms a multimer that binds to a cytokine to form a nonfunctional complex; cytokine antagonists for the treatment of cytokine-related diseases or disorders |
| 07/31/2003 | US20030143696 Human chemokine beta-13 |
| 07/31/2003 | US20030143695 Novel polypeptide and dna thereof |
| 07/31/2003 | US20030143694 Containing beta-FSH subunit covalently bound to a polypeptide segment having amino acid sequence: ser-gly-ser-asn-ala-thr-gly-ser-gly-ser-asn-ala-thr-ser-gly-se r; useful for fertility, egg production and spermatogenesis |
| 07/31/2003 | US20030143693 Growing, under suitable conditions, procaryotic or eucaryotic host cells transformed or transfected with a specific DNA, and isolating the desired polypeptide product of the expression of such DNA sequence |
| 07/31/2003 | US20030143692 Methods and compositions for modulating integrin-mediated cell-cell interactions |
| 07/31/2003 | US20030143691 Human testin |
| 07/31/2003 | US20030143689 Peptides and proteins that effect ligand transport encoded by a specific nucleic acid, useful in development of human therapeutics and diagonstic formulations and procedures |
| 07/31/2003 | US20030143687 Biologic variability of asthma associated factors useful in treating and diagnosing atopic allergies including asthma and related disorders |
| 07/31/2003 | US20030143686 Transferases |
| 07/31/2003 | US20030143685 Nucleic acid expression control sequence cassettes comprising a stable bacteriophage T5 promoter and nucleic acid regulatory sequences, useful for generating stable expressin vectors of high-level protein expression; culture product |
| 07/31/2003 | US20030143684 Combining a compound to be tested, a host cell expressing a recombinant protein containing a mammalian C-C chemokine receptor 3 and a ligand for binding of ligand to such receptor, detecting the formation of a receptor-ligand complex |
| 07/31/2003 | US20030143683 Introducing a nucleotide sequence encoding prefered amino acid sequences in into a host cell and culturing the host cell in which the peptides are expressed from the nucleotide sequence; human therapeutics and diagnostic protein |
| 07/31/2003 | US20030143681 Diagnose and treat neurological conditions |
| 07/31/2003 | US20030143676 Receptor polypeptides and polynucleotides encoding such polypeptides; for treating a disorder characterized by an elevated level of osteopontin |
| 07/31/2003 | US20030143675 Novel 38594, 57312, 53659, 57250, 63760, 49938, 32146, 57259, 67118, 67067, 62092, 8099, 46455, 54414, 53763, 67076, 67102, 44181, 67084FL, 67084ALT, FBH58295FL, 57255, and 57255alt molecules and uses therefor |
| 07/31/2003 | US20030143674 Polypeptides fused to heterologous polypeptide sequences, and an antibodies which bind to the above polypeptides |
| 07/31/2003 | US20030143672 Providing conservative or semi-conservative amino acid substitutions at positions 3 and/or 5 and/or 7 of these epitopes, useful in eliciting immune responses with respect to corresponding wildtype epitopes |
| 07/31/2003 | US20030143671 Anti-microbial polypeptides can be sequence-defined by conserved cysteine residue patterns and are termed defensins; anti-idiotypic antibody of an antibody which specifically binds to above polypeptide or protein |
| 07/31/2003 | US20030143670 Identification of three peptide agonists for the orphan GPCR( G-protein coupled receptor) designated SNORF44 |
| 07/31/2003 | US20030143668 Guanosine triphosphate-binding protein coupled receptors |
| 07/31/2003 | US20030143667 Repeat sequences of the CA125 gene and their use for diagnostic and therapeutic interventions |
| 07/31/2003 | US20030143665 Calcium independent receptor of alpha-latrotoxin,characterization and uses thereof |
| 07/31/2003 | US20030143662 Glycosulfopeptide inhibitors of leukocyte rolling and methods of use thereof |
| 07/31/2003 | US20030143656 Drug screening compounds which inhibit rate of phosphorylation by kinase having hydrophobic pocket domain; surface plasmon resonance; fusion proteins; anticancer-/ antidiabetic agents |
| 07/31/2003 | US20030143654 Which participates in the ubiquitin-dependent proteolytic pathway that targets regulatory proteins for rapid intracellular degradation |
| 07/31/2003 | US20030143633 Factors participating in degranulation of mast cells, dnas encoding the same, method of screening of these factors and the inhibitors |
| 07/31/2003 | US20030143632 Fusion proteins; tango genes; drug screening; competitive binding assay |
| 07/31/2003 | US20030143626 Such as cyclin-dependent kinases and/or bax genes/proteins covalently linked to platform compound (thioredoxin); drug screening |
| 07/31/2003 | US20030143623 Isolated human transporter proteins, nucleic acid molecules encoding human transporter proteins, and uses thereof |
| 07/31/2003 | US20030143622 Human RNA binding proteins |
| 07/31/2003 | US20030143620 Carbohydrate ligands specific for MHC molecules |
| 07/31/2003 | US20030143617 ATP synthase subunits |
| 07/31/2003 | US20030143611 Cloning the DNA sequence encoding recombinant SRTA-70 proteins |
| 07/31/2003 | US20030143610 Methods for the treatment of metabolic disorders, including obesity and diabetes |